Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New nanoparticle vaccine aims to outsmart COVID variants

NCT ID NCT07183709

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 33 times

Summary

This early-stage study tests a new type of COVID-19 booster vaccine called PepGNP-COVID19 in 60 healthy adults aged 18-64. Unlike current vaccines that focus on antibodies, this one uses tiny gold particles to train the body's T cells to recognize and fight the virus, potentially offering longer-lasting protection against new variants. The main goal is to check safety and the immune response at three different dose levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center Vaccine Research Center

    Cincinnati, Ohio, 45229, United States

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia, 20037-3201, United States

  • University of Alabama at Birmingham School of Medicine - Infectious Disease

    Birmingham, Alabama, 35222, United States

Conditions

Explore the condition pages connected to this study.